Advancing randomized controlled trials of vascular anomalies: an analysis of trial waste

No abstract is available for this paper.

• Publication year

  2024

• Venue

  European Journal of Pediatrics

• Publication date

  2024-09-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00431-024-05790-2PMID 39316124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Model-Informed individualized dosage regimen of sirolimus in pediatric patients with intractable lymphatic malformations.

  2024cited by this paper
• New Insights into Cervicofacial Vascular Anomalies

  2024cited by this paper
• Research waste among randomized controlled trials in ovarian cancer: A cross-sectional study.

  2024influential reference
• Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts’ Opinion and Systematic Review from the Literature

  2023cited by this paper
• Infectious complications of vascular anomalies treated with sirolimus: A systematic review

  2023cited by this paper
• Case report: Progressive pulmonary artery hypertension in a case of megalencephaly-capillary malformation syndrome

  2023cited by this paper
• ISSVA Classification of Vascular Anomalies and Molecular Biology

  2022cited by this paper
• STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery

  2021cited by this paper
• Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer

  2021influential reference
• Bleomycin Polidocanol Foam (BPF) Stability - In Vitro Evidence for the Effectiveness of a Novel Sclerosant for Venous Malformations.

  2020cited by this paper
• Infantile and congenital hemangiomas.

  2020cited by this paper
• Vascular malformations syndromes: an update.

  2019cited by this paper
• Research waste in surgical randomized controlled trials

  2019influential reference
• Vascular Anomalies: Diagnosis of Complicated Anomalies and New Medical Treatment Options.

  2019cited by this paper
• Harms From Uninformative Clinical Trials.

  2019cited by this paper
• Increasing value and reducing waste in biomedical research regulation and management.

  2014cited by this paper
• The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials

  2011cited by this paper
• Need to realign patient-oriented and commercial and academic research.

  2011cited by this paper
• CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials

  2010cited by this paper
• Extracranial arteriovenous malformations: natural progression and recurrence after treatment.

  2010cited by this paper
• CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

  2010cited by this paper
• Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration.

  2008cited by this paper
• The research priorities of patients attending UK cancer treatment centres: findings from a modified nominal group study

  2007cited by this paper
• Vascular anomalies: classification, diagnosis, and natural history.

  2001cited by this paper

• Research waste among randomized controlled trials in preterm infants: a Cross-sectional study

  2025cites this paper